Firefly Neuroscience, Inc.
AIFF
NASDAQ·Technology·Software - Application·Mkt cap $16.7M
$1.13
▲ +2.73%
P/E
-1.66
Mkt Cap
$16.7M
52-Wk Range
$0.62–$3.15
52-Week Range
$0.62 - $3.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 57.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and neuroscientific algorithms for objective mental health diagnosis
- Unique brain network analysis technology with clinical validation
- Dual market access to both pharmaceutical companies and clinical practitioners
- First-mover advantage in AI-powered objective neurological assessment
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
No forward estimates available
Increasing global adoption of AI in healthcare and precision medicine
Value
Valuation data unavailable
Momentum
Falling
-29.4% over 3m
Quality
Strong
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying AIFF right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 10, 2026
Most recent quarter reported revenue of $485.0K. Reported EPS of -$0.13.
Reported EPS · last 4Q
0 of 2 beats
Q3 26
—
Q2 26
—
Revenue trend · last 8Q
—
—
—
+258%
-84%
+1076%
+677%
+1028%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.9M
$33.0K
$53.0K
$43.0K
$299.0K
$388.0K
$412.0K
$485.0K
Margins · last 8Q
Gross
—
Operating
—
Profit
-413.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AIFF stacks vs Software - Application
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related